290 related articles for article (PubMed ID: 25595221)
1. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).
Jankovic J; Adler CH; Charles D; Comella C; Stacy M; Schwartz M; Manack Adams A; Brin MF
J Neurol Sci; 2015 Feb; 349(1-2):84-93. PubMed ID: 25595221
[TBL] [Abstract][Full Text] [Related]
2. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
Charles PD; Adler CH; Stacy M; Comella C; Jankovic J; Manack Adams A; Schwartz M; Brin MF
J Neurol; 2014 Jul; 261(7):1309-19. PubMed ID: 24752807
[TBL] [Abstract][Full Text] [Related]
3. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.
Jochim A; Meindl T; Mantel T; Zwirner S; Zech M; Castrop F; Haslinger B
J Neurol; 2019 Aug; 266(8):1879-1886. PubMed ID: 31049731
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
[TBL] [Abstract][Full Text] [Related]
7. Neck Pain and Cervical Dystonia: Treatment Outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
Charles PD; Manack Adams A; Davis T; Bradley K; Schwartz M; Brin MF; Patel AT
Pain Pract; 2016 Nov; 16(8):1073-1082. PubMed ID: 26910788
[TBL] [Abstract][Full Text] [Related]
8. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
[TBL] [Abstract][Full Text] [Related]
9. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
[TBL] [Abstract][Full Text] [Related]
10. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.
Trosch RM; Espay AJ; Truong D; Gil R; Singer C; LeWitt PA; Lew MF; Tagliati M; Adler CH; Chen JJ; Marchese D; Comella CL
J Neurol Sci; 2017 May; 376():84-90. PubMed ID: 28431634
[TBL] [Abstract][Full Text] [Related]
11. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.
Comella CL; Jankovic J; Shannon KM; Tsui J; Swenson M; Leurgans S; Fan W;
Neurology; 2005 Nov; 65(9):1423-9. PubMed ID: 16275831
[TBL] [Abstract][Full Text] [Related]
12. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.
Lew MF; Brashear A; Dashtipour K; Isaacson S; Hauser RA; Maisonobe P; Snyder D; Ondo W
Int J Neurosci; 2018 Jul; 128(7):619-626. PubMed ID: 29343142
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).
Jankovic J; Adler CH; Charles PD; Comella C; Stacy M; Schwartz M; Sutch SM; Brin MF; Papapetropoulos S
BMC Neurol; 2011 Nov; 11():140. PubMed ID: 22054223
[TBL] [Abstract][Full Text] [Related]
14. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study.
Dashtipour K; Mari Z; Jankovic J; Adler CH; Schwartz M; Brin MF
J Neurol Sci; 2019 Oct; 405():116413. PubMed ID: 31494402
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia.
Charles D; Brashear A; Hauser RA; Li HI; Boo LM; Brin MF;
Clin Neuropharmacol; 2012; 35(5):208-14. PubMed ID: 22948497
[TBL] [Abstract][Full Text] [Related]
16. Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment.
Jog M; Wein T; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
Can J Neurol Sci; 2016 Sep; 43(5):687-96. PubMed ID: 27430524
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.
Dressler D; Paus S; Seitzinger A; Gebhardt B; Kupsch A
J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):1014-9. PubMed ID: 23687362
[TBL] [Abstract][Full Text] [Related]
18. Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study.
Wein T; Jog M; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
Can J Neurol Sci; 2019 Nov; 46(6):742-752. PubMed ID: 31256770
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
20. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.
Poewe W; Deuschl G; Nebe A; Feifel E; Wissel J; Benecke R; Kessler KR; Ceballos-Baumann AO; Ohly A; Oertel W; Künig G
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):13-7. PubMed ID: 9436721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
